{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"0.0","value":"0.0"},{"groupId":"OG003","spread":"0.0","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.99","value":"92.5"},{"groupId":"OG001","spread":"14.43","value":"80.1"},{"groupId":"OG003","spread":"12.83","value":"84.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.12","value":"75.7"},{"groupId":"OG001","spread":"8.11","value":"90.0"},{"groupId":"OG002","spread":"1.29","value":"93.2"},{"groupId":"OG003","spread":"8.73","value":"85.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3"},{"groupId":"OG001","value":"96.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Day 85"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Percentage of PD-L1 receptors occupied by avelumab on human lymphocytes (CD3+ T-cells) was assessed by flow cytometry on peripheral blood mononuclear cell (PBMC) samples. Greater than or equal to \\[\\>=\\] 85 percent \\[%\\] of cell viability was required for reliable receptor occupancy assessment.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.","id":"OG000","title":"Dose Escalation Cohort: Avelumab 1.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG001","title":"Dose Escalation Cohort: Avelumab 3.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG002","title":"Dose Escalation Cohort: Avelumab 10.0 mg/kg"},{"description":"Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG003","title":"Dose Escalation Cohort: Avelumab 20.0 mg/kg"}],"paramType":"MEAN","populationDescription":"Safety analysis set included all participants who have received at least 1 dose of study treatment. Here \"Overall number of participants analyzed\" signifies those who were evaluable for this outcome measure and \"number analyzed\" signifies those who were evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","timeFrame":"Pre-infusion on Day 1; 48 hours after infusion on Day 3; Pre-infusion on Days 15, 43, and 85","title":"Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Programmed Death Ligand 1 (PD-L1) Receptor Occupancy","type":"SECONDARY","unitOfMeasure":"Percentage of receptors"}